Report: Isomorphic in Funding Talks at up to $50 Billion Valuation

Isomorphic Labs, an Alphabet spin-off specializing in AI-assisted drug discovery, is in early talks to raise new funding at a valuation ranging between $40 billion and $50 billion, according to tech news outlet SiliconANGLE.

The company relies on its IsoDDE platform, which aims to identify molecular binding sites and model interactions between proteins and drug compounds, essential steps in drug design prior to laboratory testing. These technologies aim to shorten the list of candidate compounds requiring physical testing, which is the most costly phase in developing any drug.

The company's previous funding round was valued at $2.1 billion last March, making any new round at these levels among the largest valuations in the biotechnology sector if closed under the reported terms. This level is particularly notable for a company that has yet to bring a pharmaceutical product to market, reflecting high expectations for the value of its research platform.

Investors are closely watching this sector as it promises to reduce the time and cost required for drug development, which typically takes many years. Isomorphic is one of the leading players in this field, thanks to its connection to Alphabet and its ability to leverage its research infrastructure, at a time when competition is intensifying to turn artificial intelligence into a practical tool for therapeutics development.

What do these terms mean?

AI Drug Discovery: The use of computational models to design drug compounds and predict their interactions with proteins, rather than relying solely on laboratory experiments at every stage.

Valuation: The estimated market value of a company as a whole, typically calculated based on the share price in the latest funding round or in comparison to peer companies.

Biotechnology: A sector that combines biological sciences and technology to develop drugs, therapies, and vaccines, increasingly relying on computational tools and artificial intelligence.